{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:35:09Z","timestamp":1792416909050,"version":"4.4.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.ctrv.2017.10.011","type":"journal-article","created":{"date-parts":[[2017,11,10]],"date-time":"2017-11-10T02:47:20Z","timestamp":1510282040000},"page":"61-73","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"C","title":["Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review"],"prefix":"10.1016","volume":"62","author":[{"given":"Maria","family":"R\u00f8ed Sk\u00e5rderud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2335-8219","authenticated-orcid":false,"given":"Anne","family":"Polk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Kjeldgaard Vistisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn Ole","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorte Lisbet","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2017.10.011_b0005","unstructured":"GLOBOCAN. Colorectal cancer fact sheet 2012, http:\/\/globocan.iarc.fr\/Pages\/fact_sheets_cancer.aspx; 2012 [accessed 20.03.17]."},{"key":"10.1016\/j.ctrv.2017.10.011_b0010","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2017.10.011_b0015","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1200\/JOP.0942001","article-title":"Impact of irinotecan and oxaliplatin on overall survival in patients with metastatic colorectal cancer: a population-based study","volume":"5","author":"Lim","year":"2009","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.ctrv.2017.10.011_b0020","doi-asserted-by":"crossref","first-page":"iii1","DOI":"10.1093\/annonc\/mdu260","article-title":"The EGWG. Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Van Cutsem","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2017.10.011_b0025","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1080\/14656566.2016.1186649","article-title":"Oral drugs in the treatment of metastatic colorectal cancer","volume":"17","author":"Kwakman","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ctrv.2017.10.011_b0030","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S1470-2045(15)70191-9","article-title":"The role of regorafenib in metastatic colorectal cancer","volume":"16","author":"Riechelmann","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2017.10.011_b0035","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ctrv.2014.02.006","article-title":"A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +\/- targeted therapy","volume":"40","author":"Nielsen","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2017.10.011_b0040","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1146\/annurev-med-051513-102539","article-title":"Recent therapeutic advances in the treatment of colorectal cancer","volume":"66","author":"Ciombor","year":"2015","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.ctrv.2017.10.011_b0045","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","article-title":"FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study","volume":"22","author":"Tournigand","year":"2004","journal-title":"J Clin Oncol: Official J Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.10.011_b0050","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/annonc\/mdw206","article-title":"Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)","volume":"27","author":"Yamazaki","year":"2016","journal-title":"Ann Oncol: Official J Eur Soc Med Oncol"},{"key":"10.1016\/j.ctrv.2017.10.011_b0055","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.clcc.2013.04.006","article-title":"FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials","volume":"12","author":"Petrelli","year":"2013","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.ctrv.2017.10.011_b0060","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study","volume":"26","author":"Saltz","year":"2008","journal-title":"J Clin Oncol: Official J Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.10.011_b0065","doi-asserted-by":"crossref","unstructured":"Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer (Oxford, England: 1990) 2012; 48: 1466\u201375.","DOI":"10.1016\/j.ejca.2012.02.057"},{"key":"10.1016\/j.ctrv.2017.10.011_b0070","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ctrv.2017.10.011_b0075","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S1470-2045(12)70345-5","article-title":"TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial","volume":"13","author":"Yoshino","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2017.10.011_b0080","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","author":"Grothey","year":"2013","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ctrv.2017.10.011_b0085","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol: Official J Eur Soc Med Oncol"},{"key":"10.1016\/j.ctrv.2017.10.011_b0090","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ijc.25864","article-title":"Regorafenib (BAY 73\u20134506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity","volume":"129","author":"Wilhelm","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2017.10.011_b0095","unstructured":"Administration USFaD. Regorafenib; 2016, https:\/\/wayback.archive-it.org\/7993\/20170113081059\/http:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm321378.htm [accessed 23.03.2017]."},{"key":"10.1016\/j.ctrv.2017.10.011_b0100","unstructured":"Agency EM. Stivarga\/Regorafenib; 2014 http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002573\/human_med_001684.jsp&mid=WC0b01ac058001d124 [accessed 20.03.2017]."},{"key":"10.1016\/j.ctrv.2017.10.011_b0105","article-title":"Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: Results from a multicenter study (REBACCA) nested within a compassionate use program","author":"Adenis","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2017.10.011_b0110","doi-asserted-by":"crossref","unstructured":"Carrato A, Benavides M, Sureda BM, Longo F, Alfonso PG, Falco E, et al. Regorafenib (REG) as a single agent for first-line treatment of frail and\/or unfit for polychemotherapy (PChT) patients (pts) with metastatic colorectal cancer (mCRC): A phase II study of the Spanish Cooperative Group for Digestive Tumor Therapy (TTD). J Clin Oncol. Conference 2016; 34: no pagination.","DOI":"10.1200\/JCO.2016.34.15_suppl.3527"},{"key":"10.1016\/j.ctrv.2017.10.011_b0115","first-page":"10","article-title":"CONSIGN-an open-label phase-3B-study of regorafenib in patients with metastatic colorectal cancer (mCRC) who failed standard therapy","volume":"39","author":"Hofheinz","year":"2016","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.ctrv.2017.10.011_b0120","doi-asserted-by":"crossref","first-page":"790","DOI":"10.4143\/crt.2014.126","article-title":"Regorafenib as salvage treatment in Korean patients with refractory metastatic colorectal cancer","volume":"47","author":"Kim","year":"2015","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2017.10.011_b0125","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","article-title":"Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"16","author":"Li","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2017.10.011_b0130","doi-asserted-by":"crossref","unstructured":"Wong ALA, Sinha A, Gopinathan A, Lim RSC, Tan CS, Soh IPT, et al. Pharmacodynamic effects of regorafenib in metastatic colorectal carcinoma (mCRC). J Clin Oncol. Conference 2013; 31: no pagnation.","DOI":"10.1200\/jco.2013.31.15_suppl.e14507"},{"key":"10.1016\/j.ctrv.2017.10.011_b0135","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.4_suppl.721","article-title":"Safety and efficacy of regorafenib post-marketing surveillance (PMS) in Japanese patients with metastatic colorectal cancer (mCRC)","volume":"35","author":"Komatsu","year":"2017","journal-title":"J Clin Oncol: Official J Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.10.011_b0140","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11523-016-0458-1","article-title":"Regorafenib in the real-life clinical practice: data from the czech registry","volume":"12","author":"Kopeckova","year":"2017","journal-title":"Targeted Oncol"},{"key":"10.1016\/j.ctrv.2017.10.011_b0145","article-title":"The real-world use of regorafenib for metastatic colorectal cancer: Multicentre analysis of treatment pattern and outcomes in Hong Kong","author":"Lam","year":"2016","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.ctrv.2017.10.011_b0150","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.4_suppl.769","article-title":"Clinical efficacy and safety of regorafenib (REG) in the treatment of metastatic colorectal cancer (mCRC) in daily practice in Germany: Interim results of the prospective multicentre noninterventional RECORA study","volume":"35","author":"Schulz","year":"2017","journal-title":"J Clin Oncol: Official J Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.10.011_b0155","doi-asserted-by":"crossref","first-page":"34811","DOI":"10.18632\/oncotarget.9187","article-title":"Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer","volume":"7","author":"Suenaga","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2017.10.011_b0160","doi-asserted-by":"crossref","unstructured":"Wakatsuki T, Shinozaki E, Suenaga M, Nakayama I, Matsushima T, Osumi H, et al. Associations between regorafenib-induced adverse events (AEs) and efficacy in metastatic colorectal cancer (mCRC). J Clin Oncol: Official J Am Soc Clin Oncol 2017; 35: no pagnation.","DOI":"10.1200\/JCO.2017.35.4_suppl.556"},{"key":"10.1016\/j.ctrv.2017.10.011_b0165","doi-asserted-by":"crossref","unstructured":"Gomes DBD, Hassabo HM, Al Mutar SS, Sahin IH, Rogers J, Nguyen DV, et al. MD Anderson experience with off-study regorafenib in patients with advanced colorectal cancer. Journal of Clinical Oncology. Conference 2014; 32: no pagnation.","DOI":"10.1200\/jco.2014.32.3_suppl.635"},{"key":"10.1016\/j.ctrv.2017.10.011_b0170","doi-asserted-by":"crossref","unstructured":"Hasan T, Mamo A, Kavan T, Rho YS, Kavan P. Canadian experience managing dose intensity of regorafenib in relation to safety and clinical outcome in metastatic colorectal cancer patients. Journal of Clinical Oncology. Conference 2016; 34: no pagnation.","DOI":"10.1200\/JCO.2016.34.15_suppl.e15154"},{"key":"10.1016\/j.ctrv.2017.10.011_b0175","first-page":"371","article-title":"Reduced dose of salvage-line regorafenib monotherapy for metastatic colorectal cancer in Japan","volume":"35","author":"Hirano","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctrv.2017.10.011_b0180","doi-asserted-by":"crossref","unstructured":"Masuishi T, Taniguchi H, Hamauchi S, Komori A, Kito Y, Narita Y, et al. Regorafenib versus trifluridine\/tipiracil for refractory metastatic colorectal cancer: a retrospective comparison. Clinl Colorectal Cancer; 2016; no pagnation.","DOI":"10.1016\/j.clcc.2016.07.019"},{"key":"10.1016\/j.ctrv.2017.10.011_b0185","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.4_suppl.778","article-title":"Updated analysis: A retrospective study evaluating the safety and efficacy of regorafenib in patients with metastatic colorectal cancer - HGCSG1401","volume":"35","author":"Ota","year":"2017","journal-title":"J Clin Oncol: Official J Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.10.011_b0190","doi-asserted-by":"crossref","first-page":"v60","DOI":"10.1093\/annonc\/mdu435.70","article-title":"Experience with regorafenib treatment for metastatic colorectal cancer at Aichi cancer center","volume":"25","author":"Uegaki","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2017.10.011_b0195","doi-asserted-by":"crossref","first-page":"33982","DOI":"10.18632\/oncotarget.5053","article-title":"Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: implications for clinical management","volume":"6","author":"Del Prete","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2017.10.011_b0200","doi-asserted-by":"crossref","first-page":"ii47","DOI":"10.1093\/annonc\/mdw199.153","article-title":"Regorafenib vs TAS-102 as salvage-line treatment in patients with metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study","volume":"27","author":"Kotaka","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2017.10.011_b0205","doi-asserted-by":"crossref","first-page":"e0145004","DOI":"10.1371\/journal.pone.0145004","article-title":"Clinical implication of anti-angiogenic effect of regorafenib in metastatic colorectal cancer","volume":"10","author":"Lim","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2017.10.011_b0210","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.4_suppl.700","article-title":"Safety and effevtiveness of regorafenib (REG) in patients with metastatic colorectal cancer (mCRC) in routine clinical practice: An interim analysis (IA) from the prospective, observational CORRELATE study","volume":"35","author":"Ducreux","year":"2017","journal-title":"J Clin Oncol: Official J Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.10.011_b0215","doi-asserted-by":"crossref","unstructured":"Miyamoto Y, Yuki S, Shimokawa M, Tanioka H, Tsuji A, Asayama M, et al. A randomized, double-blind, placebo-controlled phase II study of prophylactic dexamethasone (dex) therapy for fatigue and malaise due to regorafenib in patient (pts) with metastatic colorectal cancer (mCRC): (KSCC1402\/HGCSG1402). J Clin Oncol Conf 2016; 34: no pagnation.","DOI":"10.1200\/JCO.2016.34.15_suppl.10127"},{"key":"10.1016\/j.ctrv.2017.10.011_b0220","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","article-title":"Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer","volume":"25","author":"Van Cutsem","year":"2007","journal-title":"J Clin Oncol: Official J Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.10.011_b0225","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3816\/CCC.2007.n.038","article-title":"Role of tyrosine kinase inhibitors in the treatment of advanced colorectal cancer","volume":"6","author":"Gravalos","year":"2007","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.ctrv.2017.10.011_b0230","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1586\/era.09.41","article-title":"Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial","volume":"9","author":"Rimassa","year":"2009","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ctrv.2017.10.011_b0235","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S1470-2045(13)70154-2","article-title":"Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial","volume":"14","author":"Cunningham","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2017.10.011_b0240","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/annonc\/mdp359","article-title":"Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study","volume":"21","author":"Rosati","year":"2010","journal-title":"Ann Oncol: Official J Eur Soc Med Oncol"},{"key":"10.1016\/j.ctrv.2017.10.011_b0245","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s00520-013-2085-z","article-title":"Prevention and management of adverse events related to regorafenib","volume":"22","author":"De Wit","year":"2014","journal-title":"Supportive Care Cancer: Official J Multinational Assoc Supportive Care Cancer"},{"key":"10.1016\/j.ctrv.2017.10.011_b0250","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1007\/s12094-014-1212-8","article-title":"Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer","volume":"16","author":"Sastre","year":"2014","journal-title":"Clin Translational Oncol: Official Publ Federation Spanish Oncol Societies Natl Cancer Inst Mexico"},{"key":"10.1016\/j.ctrv.2017.10.011_b0255","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/1756283X15580743","article-title":"Management of regorafenib-related toxicities: a review","volume":"8","author":"Krishnamoorthy","year":"2015","journal-title":"Therapeutic Adv Gastroenterol"},{"key":"10.1016\/j.ctrv.2017.10.011_b0260","unstructured":"FDA. Nexavar (srafenib) tablets prescribing information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/021923s016lbl.pdf; 2013 [accessed 2017]."},{"key":"10.1016\/j.ctrv.2017.10.011_b0265","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2230.2011.04060.x","article-title":"Meta-analysis of dermatological toxicities associated with sorafenib","volume":"36","author":"Zhang","year":"2011","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.ctrv.2017.10.011_b0270","doi-asserted-by":"crossref","unstructured":"Sternberg CN, Hawkins RE, Wagstaff J, Salman P, Mardiak J, Barrios CH. A randomised, double-blind phase III study of pazopanib in patients with advanced and\/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer (Oxford, England: 1990) 2013; 49: 1287\u201396.","DOI":"10.1016\/j.ejca.2012.12.010"},{"key":"10.1016\/j.ctrv.2017.10.011_b0275","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s40265-014-0243-3","article-title":"Pazopanib: a review of its use in the management of advanced renal cell carcinoma","volume":"74","author":"McCormack","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.ctrv.2017.10.011_b0280","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1634\/theoncologist.2011-0115","article-title":"Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer","volume":"16","author":"Gomez","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2017.10.011_b0285","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.cjca.2014.02.011","article-title":"Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome","volume":"30","author":"Small","year":"2014","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.ctrv.2017.10.011_b0290","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.semnephrol.2010.09.007","article-title":"Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker","volume":"30","author":"Robinson","year":"2010","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.ctrv.2017.10.011_b0295","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3892\/mco.2017.1145","article-title":"Response to regorafenib at an initial dose of 120 mg as salvage therapy for metastatic colorectal cancer","volume":"6","author":"Osawa","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.10.011_b0300","doi-asserted-by":"crossref","unstructured":"Martinelli E, Sforza V, Cardone C, Capasso A, Nappi A, Martini G, et al., Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment; 2017.","DOI":"10.1136\/esmoopen-2017-000177"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737217301810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737217301810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T14:10:45Z","timestamp":1603289445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737217301810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":60,"alternative-id":["S0305737217301810"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2017.10.011","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2017.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}